AIM ImmunoTech Inc. filings document an immuno-pharma issuer centered on Ampligen (rintatolimod) and its public-company financing, clinical and governance disclosures. Recent 8-K reports cover material agreements, Regulation FD clinical updates for the DURIPANC pancreatic cancer study, amendments to equity distribution arrangements, warrant notices, and operating and financial results.
Registration statements and related exhibits disclose rights-offering terms, Series G Convertible Preferred Stock, common stock purchase warrants, beneficial-ownership limits, warrant agency arrangements, and shelf or at-the-market equity issuance mechanics. The filings also address risk factors, shareholder-rights modifications, corporate-governance items and capital-structure changes relevant to AIM's research-and-development drug business.
AIM ImmunoTech Inc. CEO and President Thomas K. Equels reported changes in his holdings of derivative securities related to a rights offering. On March 6, 2026, he held 25 shares of Series G Convertible Preferred Stock, each with a stated value of $1,000 and convertible into 1,000 shares of common stock, issued as part of a subscription right in a rights offering. He also reported 50,000 Class G Warrants, each exercisable for one share of common stock at an exercise price of $1.00 per share, likewise issued as part of a subscription right in a rights offering. Following these transactions, he directly held 38,922 shares of common stock.
AIM ImmunoTech director David I. Chemerow reported new derivative holdings tied to a rights offering. He now holds 25 shares of Series G Convertible Preferred Stock, each with a stated value of $1,000 and convertible into 1,000 shares of common stock, issued through a subscription right in a rights offering.
He also reported 50,000 Class G Warrants, each exercisable for one share of common stock at an exercise price of $1.00, likewise issued as part of a subscription right in a rights offering. Following these transactions, he directly holds 3,441 shares of common stock, alongside the preferred shares and warrants.
AIM ImmunoTech Inc. completed a previously announced rights offering, raising approximately $1.8 million by selling 1,842 units. Each unit included one share of Series G Convertible Preferred Stock and Class G warrants.
The company created a new Series G preferred series of 12,000 shares, each with a stated value of $1,000 and initially convertible into common stock at $1.00 per share, subject to standard anti-dilution adjustments. Conversions are limited so that holders generally cannot exceed 4.99% beneficial ownership, adjustable by the holder up to 9.99%. The rights offering also issued 3,684,000 Class G warrants, each exercisable for one share of common stock at $1.00 per share for five years. The Series G preferred is non-voting (with limited exceptions), participates with common stock in dividends and liquidation on an as-converted basis, and has no mandatory redemption features.
AIM ImmunoTech Inc. is offering Subscription Rights to purchase up to 12,000 Units. Each Unit carries one share of Series G Convertible Preferred Stock (convertible at a $1.00 conversion price) and 2,000 Warrants exercisable at $1.00 per share, representing up to 24,000,000 Warrant shares and up to 12,000,000 common shares issuable on conversion.
The Rights Offering has a subscription price of $1,000 per Unit, a Record Date of February 10, 2026, and an expiration date of March 3, 2026. The supplement revises earlier terms by lowering the conversion and exercise prices to $1.00 and increasing the number of Warrants to 24,000,000.
ImmunoTech Inc. is conducting a rights offering of up to 12,000 Units at $1,000 per Unit, for up to $12 million in gross proceeds. Each Unit includes one share of Series G convertible preferred stock plus 1,666 five-year warrants, each warrant exercisable at $1.20 per share.
Each preferred share is convertible into common stock at $1.20 per share, so a fully subscribed offering would add up to 9,996,000 shares from conversions and 19,992,000 shares from warrant exercises. Existing common and specified warrant and option holders receive one non‑transferable subscription right per share as of February 10, 2026, with rights expiring on February 27, 2026.
The company expects net proceeds of about $10.65 million if fully subscribed, before other expenses and excluding any warrant exercise proceeds, and plans to use the cash for general corporate purposes, including clinical trial and manufacturing costs for pancreatic cancer programs, and to repay certain debt.
ImmunoTech Inc. filed Amendment No. 3 to its Form S-1 registration statement as an exhibits-only update, amending Item 16(a) in Part II while leaving the remainder of the registration statement unchanged.
The amendment provides a detailed estimate of issuance and distribution expenses totaling $272,262, including an SEC registration fee of $4,971.60, a FINRA filing fee of $5,900.00, and legal, accounting, agent and miscellaneous fees. It also restates Delaware law-based indemnification provisions for directors and officers, summarizes prior unregistered securities issuances to executives and directors under Section 4(a)(2) and Rule 701, lists extensive material contracts and corporate documents as exhibits, and includes standard Securities Act undertakings and signature blocks.
ImmunoTech Inc. director David I. Chemerow reported an indirect acquisition of common stock through The David I Chemerow 1992 Trust. On 02/05/2026, the trust acquired 2,800 shares of ImmunoTech common stock at a price of $1.23 per share.
Following this transaction, the trust beneficially owned a total of 3,441 ImmunoTech common shares, all reported as indirectly held on behalf of Chemerow.
ImmunoTech Inc. filed a current report describing new investor and clinical update materials. The company furnished a February 2026 corporate presentation, a DURIPANC year-end interim clinical progress update, and a February 5, 2026 press release as exhibits, noting these are furnished rather than filed for liability purposes.
The update relates to an ongoing Phase I/II open-label study combining durvalumab (Imfinzi) and rintatolimod (Ampligen) in pancreatic cancer patients with stable disease after FOLFIRINOX therapy. ImmunoTech emphasizes that Ampligen is still under evaluation across several diseases and that significant additional testing and human trials are required, with no assurance of successful or favorable outcomes.
ImmunoTech Inc. is launching a rights offering registering subscription rights to purchase up to 12,000 Units, each with one Series G Convertible Preferred share, plus securities convertible into up to 9,996,000 common shares and exercisable for up to 19,992,000 additional common shares.
Each Unit is offered at a $1,000 subscription price, with one non-transferable right per common share (including shares underlying participating options and warrants) held as of February 10, 2026, and an over-subscription privilege. The offer is best-efforts, with no minimum proceeds and an expected net raise of about $10.65 million if fully subscribed.
The company plans to use proceeds for general corporate purposes, clinical and manufacturing costs for prospective Phase 2/3 pancreatic cancer trials, and repayment of certain debt. The offering also supports efforts to regain NYSE American equity compliance while advancing Ampligen-based oncology, antiviral, ME/CFS and post-COVID programs.